Objective: To determine whether a therapeutic dose of docosahexaenoic acid (DH A), an ω-3 fatty acid, will slow the course of retinal degeneration in adult p atients with retinitis pigmentosa who are also receiving v...Objective: To determine whether a therapeutic dose of docosahexaenoic acid (DH A), an ω-3 fatty acid, will slow the course of retinal degeneration in adult p atients with retinitis pigmentosa who are also receiving vitamin A. Design: Rand omized, controlled, double-masked trial of 221 patients, aged 18 to 55 years, e valuated over a 4-year interval. Patients were given either 1200 mg/d of docosa hexaenoic acid or control capsules. All were given 15000 IU/d of vitamin A (give n as retinyl palmitate). Randomization considered genetic type and baseline diet ary ω-3 fatty acid intake. Main Outcome Measures: The primary outcome measure was the total point score for the 30-2 program of the Humphrey field analyzer; secondary outcome measures were the total point score for the 30-2 and 30/60-1 programs combined, 30-Hz electroretinogram amplitude, and Early Treatment Diab etic Rentinopathy Study visual acuity. Results: No significant differences in de cline in ocular function were found between the docosahexaenoic acid plus vitami n A (DHA +A) group and control plus vitamin A (control +A)-group over a 4-ye ar interval among all 221 randomized patients or among the 208 patients who comp leted all 4 follow-up visits. The mean annual rate of loss of sensitivity for the Humphrey Field Analyzer 30-2 programwas 37 dB for the DHA +A group and 38 dB for the control +A group (P=0.88). For the Humphrey Field Analyzer 30-2 and 30/60-1 programs combined, the mean annual rates of loss of field sensitivity were 57 dB for the DHA +A group and 60 dB (P=0.73) for contro l +A group. No toxic adverse effects were observed. No significant differences by treatment group assignment were observed within genetic types or within the c ategory of baseline ω-3 fatty acid intake. Conclusion: In patients assigned to receive 15000 IU/d of vitamin A, this randomized trial showed that 1200 mg/d of docosahexaenoic acid supplementation over a 4-year interval did not, on averag e, slow the course of disease in patients with retinitis pigmentosa.展开更多
Objective: To determine whether docosahexaenoic acid will slow the course of r etinal degeneration in subgroups of patients with retinitis pigmentosa who are r eceiving vitamin A. Design: Acohort of 208 patients with ...Objective: To determine whether docosahexaenoic acid will slow the course of r etinal degeneration in subgroups of patients with retinitis pigmentosa who are r eceiving vitamin A. Design: Acohort of 208 patients with retinitis pigmentosa, a ged 18 to 55 years, were randomly assigned to 1200 mg of docosahexaenoic acid pl us 15000 IU/d of vitamin A given as retinyl palmitate (DHA +A group) or control fatty acid plus 15000 IU/d of vitamin A (control +A group) and followed up ove r 4 years. Seventy percent of the patients in each group were taking vitamin A, 15000 IU/d, prior to entry. We compared rates of decline in ocular function in t he DHA +A vs control +A groups among the subgroups defined by use or nonuse of vitamin A prior to entry. We also determined whether decline in ocular function was related to red blood cell phosphatidylethanolamine docosahexaenoic acid lev el, dietary ω-3 fatty acid intake, or duration of vitamin A use. Main outcome measures were Humphrey Field Analyzer visual field sensitivity, 30-Hz electrore tinogram amplitude, and visual acuity. Results: Among patients not taking vitami n A prior to entry, those in the DHA +A group had a slower decline in field sen sitivity and electroretinogram amplitude than those in the control +A group ove r the first 2 years (P=.01 and P=.03, respectively); these differences were not observed in years 3 and 4 of follow-up or among patients taking vitamin A prior to entry. In the entire cohort, red blood cell phosphatidylethanolamine docosah exaenoic acid level was inversely related to rate of decline in total field sens itivity over 4 years (test for trend, P=0.05). This was particularly evident ove r the first 2 years among those not on vitamin A prior to entry (test for trend, P=0.003). In the entire control +A group, dietary ω-3 fatty acid intake was inversely related to loss of total field sensitivity over 4 years (intake,< 0.20 vs ≥0.20 g/d; P= 0.02). The duration of vitamin A supplementation prior to ent ry was inversely related to rate of decline in electroretinogram amplitude (P=.0 08). Conclusions: For patients with retinitis pigmentosa beginning vitamin A the rapy, addition of docosahexaenoic acid, 1200 mg/d, slowed the course of disease for 2 years. Among patients on vitamin A for at least 2 years, a diet rich in ω -3 fatty acids (≥0.20 g/d) slowed the decline in visual field sensitivity.展开更多
文摘Objective: To determine whether a therapeutic dose of docosahexaenoic acid (DH A), an ω-3 fatty acid, will slow the course of retinal degeneration in adult p atients with retinitis pigmentosa who are also receiving vitamin A. Design: Rand omized, controlled, double-masked trial of 221 patients, aged 18 to 55 years, e valuated over a 4-year interval. Patients were given either 1200 mg/d of docosa hexaenoic acid or control capsules. All were given 15000 IU/d of vitamin A (give n as retinyl palmitate). Randomization considered genetic type and baseline diet ary ω-3 fatty acid intake. Main Outcome Measures: The primary outcome measure was the total point score for the 30-2 program of the Humphrey field analyzer; secondary outcome measures were the total point score for the 30-2 and 30/60-1 programs combined, 30-Hz electroretinogram amplitude, and Early Treatment Diab etic Rentinopathy Study visual acuity. Results: No significant differences in de cline in ocular function were found between the docosahexaenoic acid plus vitami n A (DHA +A) group and control plus vitamin A (control +A)-group over a 4-ye ar interval among all 221 randomized patients or among the 208 patients who comp leted all 4 follow-up visits. The mean annual rate of loss of sensitivity for the Humphrey Field Analyzer 30-2 programwas 37 dB for the DHA +A group and 38 dB for the control +A group (P=0.88). For the Humphrey Field Analyzer 30-2 and 30/60-1 programs combined, the mean annual rates of loss of field sensitivity were 57 dB for the DHA +A group and 60 dB (P=0.73) for contro l +A group. No toxic adverse effects were observed. No significant differences by treatment group assignment were observed within genetic types or within the c ategory of baseline ω-3 fatty acid intake. Conclusion: In patients assigned to receive 15000 IU/d of vitamin A, this randomized trial showed that 1200 mg/d of docosahexaenoic acid supplementation over a 4-year interval did not, on averag e, slow the course of disease in patients with retinitis pigmentosa.
文摘Objective: To determine whether docosahexaenoic acid will slow the course of r etinal degeneration in subgroups of patients with retinitis pigmentosa who are r eceiving vitamin A. Design: Acohort of 208 patients with retinitis pigmentosa, a ged 18 to 55 years, were randomly assigned to 1200 mg of docosahexaenoic acid pl us 15000 IU/d of vitamin A given as retinyl palmitate (DHA +A group) or control fatty acid plus 15000 IU/d of vitamin A (control +A group) and followed up ove r 4 years. Seventy percent of the patients in each group were taking vitamin A, 15000 IU/d, prior to entry. We compared rates of decline in ocular function in t he DHA +A vs control +A groups among the subgroups defined by use or nonuse of vitamin A prior to entry. We also determined whether decline in ocular function was related to red blood cell phosphatidylethanolamine docosahexaenoic acid lev el, dietary ω-3 fatty acid intake, or duration of vitamin A use. Main outcome measures were Humphrey Field Analyzer visual field sensitivity, 30-Hz electrore tinogram amplitude, and visual acuity. Results: Among patients not taking vitami n A prior to entry, those in the DHA +A group had a slower decline in field sen sitivity and electroretinogram amplitude than those in the control +A group ove r the first 2 years (P=.01 and P=.03, respectively); these differences were not observed in years 3 and 4 of follow-up or among patients taking vitamin A prior to entry. In the entire cohort, red blood cell phosphatidylethanolamine docosah exaenoic acid level was inversely related to rate of decline in total field sens itivity over 4 years (test for trend, P=0.05). This was particularly evident ove r the first 2 years among those not on vitamin A prior to entry (test for trend, P=0.003). In the entire control +A group, dietary ω-3 fatty acid intake was inversely related to loss of total field sensitivity over 4 years (intake,< 0.20 vs ≥0.20 g/d; P= 0.02). The duration of vitamin A supplementation prior to ent ry was inversely related to rate of decline in electroretinogram amplitude (P=.0 08). Conclusions: For patients with retinitis pigmentosa beginning vitamin A the rapy, addition of docosahexaenoic acid, 1200 mg/d, slowed the course of disease for 2 years. Among patients on vitamin A for at least 2 years, a diet rich in ω -3 fatty acids (≥0.20 g/d) slowed the decline in visual field sensitivity.
